Chemotherapy-Induced Peripheral Neuropathy Impacts Quality of Life and Activities of Daily Living of Brazilian Multiple Myeloma Patients.

Autor:	de Miranda Drummond PL; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Ezequiel Dias Foundation, Regulatory Affairs, Belo Horizonte, Brazil., Dos Santos RMM; Ezequiel Dias Foundation, Regulatory Affairs, Belo Horizonte, Brazil., Silveira LP; Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Malta JS; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Moreira Reis AM; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Costa NL; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., de Paula E Silva RO; Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Fagundes EM; Hematológica clinic, Grupo Oncoclínicas, Belo Horizonte, Brazil., de Pádua CAM; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Jazyk:	angličtina
Zdroj:	Current drug safety [Curr Drug Saf] 2024; Vol. 19 (3), pp. 356-367.
DOI:	10.2174/1574886318666230817162424
Abstrakt:	Background: Survival in multiple myeloma (MM) has improved in the past years with the introduction of immunomodulators and proteasome inhibitors. However, chemotherapyinduced peripheral neuropathy (CIPN) is associated with both drug classes affecting Health- Related Quality of Life (HRQoL) and activities of daily living (ADL). Objective: We evaluated CIPN in MM patients to identify associated factors and impacts on HRQoL and ADL. Methods: This is a cross-sectional study with Brazilian patients from public and private health services. Patients were interviewed using validated tools to measure CIPN and HRQoL, along with sociodemographic and clinical questions. Logistic regression was used to assess the association of CIPN with sociodemographic, clinical, and HRQoL variables. Results: In total, 217 patients were eligible for the study. The median age was 67, 50.9% were women, 51.6% had low income, 47.5% had low education, and 55.3% attended private health services. The chemotherapy regimen most used was the combination of cyclophosphamide, thalidomide, and dexamethasone (17.5%) among the 24 types of regimens found. Most patients (90.3%) had at least one CIPN symptom: 62.7% were severe, and 51.62% were extremely bothered ADL. Numbness was the most common symptom (40.6%). CIPN was independently associated with education, hospitalization, chemotherapy, side effects, disease symptoms, and global health status in HRQoL. Conclusion: MM patients showed a high frequency of CIPN, which affected ADL and impaired HRQoL. Early and accurate detection of CIPN and dose management in patients with thalidomide and bortezomib-based regimens should be performed to provide better treatment outcomes and avoid permanent disabilities. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu